Why the study?
Does dual antiplatelet therapy (clopidogrel-aspirin) improve outcomes in patients with minor ischemic stroke or high-risk TIA?
Does dual antiplatelet therapy (clopidogrel-aspirin) improve outcomes in patients with minor ischemic stroke or high-risk TIA?
The clinical benefit of dual antiplatelet therapy with clopidogrel and aspirin is concentrated in the first 21 days following a minor ischemic stroke or high-risk TIA.
Answers are grounded in this paper and cite their sources.
Supports limiting dual antiplatelet therapy to 21 days after minor stroke or TIA to reduce bleeding; extends POINT/CHANCE evidence on time-dependent benefit.
In this analysis of the POINT and CHANCE trials, the benefit of dual antiplatelet therapy appeared to be confined to the first 21 days after minor ischemic stroke or high-risk TIA.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: